
---
title: '强势反弹！医药大白马底部崛起，板块掀涨停潮，13股获得百家以上机构抱团持仓'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202109/W020210906716952221530.png'
author: 证券时报网
comments: false
date: Mon, 06 Sep 2021 18:57:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202109/W020210906716952221530.png'
---

<div>   
<p>估值重回合理区间，医药板块掀涨停潮，中药股表现强劲。 </p><p><strong>超跌反弹，中药板块多股强势涨停</strong></p><p>9月6日，医药板块强势反弹，在<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300015" code="300015">爱尔眼科</a>等医药大白马的带动下，中药股表现较好，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002349" code="002349">精华制药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600771" code="600771">广誉远</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600976" code="600976">健民集团</a>等强势涨停，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600351" code="600351">亚宝药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300108" code="300108">吉药控股</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002390" code="002390">信邦制药</a>等均站上板块涨幅前列，早盘涨幅均超过5%。 </p><p>消息面上，上周末国药集团中国生物血液制品板块企业<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600161" code="600161">天坛生物</a>研制的静注COVID-19人免疫球蛋白（pH4）（以下简称“新冠特免”）获批开展临床试验也无疑是好消息。中国生物是在全球范围内唯一在新冠抗疫领域研制4款新冠疫苗、3款诊断试剂、2款治疗药物的生物制品企业。</p><p>医药股在经历了去年一年的暴涨后，进入2021年以来深度调整，这些公司的特点都是从底部开始反弹。前期调整下，目前医药生物行业的估值水平已经到了19年中旬，在历史上处于偏低的水平。</p><p style="text-align:center"><img data-ratio="0.9207317" src="https://data.stcn.com/djsj/202109/W020210906716952221530.png" data-type="png" data-w="820" data-imgqrcoded="1" style="margin: 0px; padding: 0px; max-width: 100%; vertical-align: middle; box-sizing: border-box; height: 460.366px; overflow-wrap: break-word !important; width: 500px;" width="500px" height="460.3658536585366px" oldsrc="W020210906716952221530.png" referrerpolicy="no-referrer"></p><p><strong>医药股再获关注，机构频频调研</strong></p><p>近期，不少券商频频调研医药股，机构调研或预示着公司有料，提前被关注，资金有望提前埋伏。8月29日，上市公司<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002019" code="002019">亿帆医药</a>发布了2021年半年报，实现营收23.77亿，同比减少15.41%；归母净利润2.13亿，同比减少70.33%；扣非净利润1.84亿，同比减少73.71%。公司业绩下滑主要受外部行业环境变化影响，包括药品集中带量采购和维生素市场整体供大于求。在公司9月1日的线上调研会，引来了30多家机构的关注和参与，名单中同时出现了高瓴、凯雷资本两大知名PE。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>近一周合计获得700多家机构的调研，包括107家基金公司、90家证券公司、98家私募、27家保险公司等。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600085" code="600085">同仁堂</a>等股近期均获得5家以上机构调研。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS601788" code="601788">光大证券</a>分析报告表示，疫苗、CXO、医疗器械、医疗服务、中药等高景气度赛道业绩持续高增长，医药流通、化学制剂等赛道则进一步分化、集中度提升。当下医药行业政策变化较大，但主线十分清晰。投资者需要把握符合国家大政方针的主赛道，即人口结构升级+绿色经济+创新升级+国际化。</p><p><strong>近万亿中药股估值回调，13股获百家以上机构持仓</strong></p><p>调整之后，估值重回合理区间，中药股有望迎来上涨的机会。据统计，A股市场涉及中药的股票有70只，市值合计9800多亿元，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600332" code="600332">白云山</a>市值位居前三，前2股市值超过1000亿元，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600332" code="600332">白云山</a>估值不到30倍，相对较低。中报业绩较好的有<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002433" code="002433">太安堂</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600129" code="600129">太极集团</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002750" code="002750">龙津药业</a>，2021上半年净利润增幅均超过400%。</p><p>进一步来看，中药股中有13家获百家以上机构抱团持仓，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>获400家以上机构持仓，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600085" code="600085">同仁堂</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600332" code="600332">白云山</a>获200家以上机构抱团持仓。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002390" code="002390">信邦制药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600329" code="600329">中新药业</a>的机构预测目标价较当前股价上涨空间超过40%；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002390" code="002390">信邦制药</a>是从事纯天然植物类中成药的研发、生产和销售的企业；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600329" code="600329">中新药业</a>具有全国领先的中药制药生产基地。（数据宝 张娟娟）</p><p style="text-align:center"><img data-ratio="0.8693694" src="https://data.stcn.com/djsj/202109/W020210906716953591767.png" data-type="png" data-w="444" data-imgqrcoded="1" style="margin: 0px; padding: 0px; max-width: 100%; height: auto !important; overflow-wrap: break-word !important; vertical-align: middle; box-sizing: border-box;" oldsrc="W020210906716953591767.png" referrerpolicy="no-referrer"></p><p>声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。</p>
  
</div>
            